by NMS Group | May 13, 2022 | Uncategorized
Nerviano, 13 May 2022 MPS1, also known as monopolar spindle 1, is a protein kinase which is over-expressed and hyperactivated in different tumors and which plays a critical role in the control of mitosis (cell division) by regulating a process called the Spindle...
by NMSGroup | May 5, 2022 | News, News, News, News
Nerviano, 5 May 2022 Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancers, today announces the new organizational structure and key appointments of the new...
by NMS Group | May 5, 2022 | 2022, 2022, 2022, 2022, 2022
Nerviano, 5 May 2022 NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A search for a...
by NMS Group | Feb 7, 2022 | News
Nerviano, 7 February 2022 NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of the...
by NMSGroup | Jan 17, 2022 | Uncategorized
Nerviano, 17 January 2022 The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are Hugues Dolgos,...
Welcome and Check out our new motion picture!
Recent Comments